Elsevier

Radiotherapy and Oncology

Volume 57, Issue 2, 1 November 2000, Pages 195-200
Radiotherapy and Oncology

Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation

https://doi.org/10.1016/S0167-8140(00)00219-XGet rights and content

Abstract

Background and purpose: To evaluate changes of the volume of the cancerous prostatic gland during androgen deprivation (AD) started immediately after diagnosis (IAD). Hypothetically, these data would assist the radiotherapist to determine the appropriate duration of pre-radiotherapy downsizing neoadjuvant luteinizing hormone releasing hormone (LHRH) treatment. A second aim was to assess any increase of the prostatic volume during the 1st year of diagnosis in patients who were allocated to a deferred treatment policy (DAD).

Methods and patients: Thirteen patients in the IAD cohort and 13 patients in the DAD group, all with T1-3pN1-2M0 prostate cancer, had regular computed tomography/magnetic resonance (CT/MR) examinations during the 1st year after randomization within the EORTC-GU trial 30846. Pre-treatment prostate specific antigen (PSA) values were available in only 12 patients.

Results: In the IAD group the prostate gland decreased with significant difference as compared with the DAD patients (P=0.033). As compared with the pre-treatment situation the prostate gland in the IAD group was reduced in size by 18, 35, and 46% at 1, 6, and 12 months, respectively. In four of six evaluable IAD patients the prostatic volume continued to shrink after achievement of the nadir PSA level (at 3 months).In three of the 13 DAD patients the prostate volume increased by >25% during the 1st 3 months after randomization.

Conclusions: If neoadjuvant androgen deprivation is applied before local treatment to downsize the volume of the cancerous prostate gland, our limited data suggest that such treatment should last at least 6 months in order to achieve a maximal effect in the majority of patients. In about 1/4 of untreated patients an increase in the prostate volume by >25% may occur within 3 months of diagnosis. If no AD is given, radiotherapy should start within this period.

Introduction

Prostate cancer has become the most common cancer in men in the Western countries, and the incidence is increasing. Only patients with prostate cancer confined to the gland (pT1-T2N0M0) are true candidates for curative treatment, either by radical prostatectomy or definitive radiotherapy. In patients with metastatic disease androgen deprivation (AD) has represented the standard palliative treatment in case of distant metastases. However, the optimal treatment for patients with loco-regionally advanced disease remains controversial [6], [16]. In asymptomatic patients one principal question is whether hormone manipulation should be started immediately after diagnosis or after clinical progression.

During the last decade medical AD has been used as neoadjuvant treatment before radical prostatectomy or high dose radiotherapy with the aim to reduce the prostatic volume. The main expectation was that such ‘downsizing’ would reduce the number of patients with tumour positive margins in the prostatectomy specimen or would facilitate the use of reduced target volumes during radiotherapy [1], [12]. So far, pre-prostatectomy neo-adjuvant hormone treatment has, however, not shown to increase overall survival, whereas the combination of radiotherapy with long-lasting AD has confirmed a beneficial overall survival in at least one study [3].

Usually, a 3 month period of treatment with a LHRH-agonist (luteinizing hormone releasing hormone) is recommended (with or without anti-androgens) before curative local treatment [10], [12], [15]. The optimal duration of neoadjuvant hormone treatment has, however, never been scientifically established. On the other hand, experience from metastatic patients suggests that more than 3 months of AD is necessary to achieve the maximal volume reduction of the prostate [2], [14] or nadir values of prostate specific antigen (PSA) [8]. The answer to the question about the duration of pre-radiotherapy neoadjuvant AD that leads to maximal volume reduction has significant impact in clinical radiation oncology. Radiobiological considerations suggest that dose escalation of >70 Gy in the 95% isodose is necessary to eradicate adenocarcinoma. Conformal radiotherapy makes such dose increase feasible, but requires the smallest possible target volume to protect normal tissue [4], [9], [11].

Localized prostate cancer is usually regarded as a slowly growing malignancy [5], [15]. A delay of 1–3 months between the initial diagnosis and definitive treatment is most often considered to be without clinical relevance. Delay periods of greater than 3 months are, however, not unusual due to the hospital waiting lists and/or lengthy staging procedures as pelvic lymphadenectomy. The question remains whether and how often significant growth of the prostatic tumour can be observed during the initial months after diagnosis.

Obviously more objective information about the size changes of hormonally treated or untreated prostate cancer is desirable in order to establish which time interval between diagnosis and local curative treatment may be allowed to elapse in clinical practice. With this background we have investigated the effect of 1 year's AD on the volume of the cancerous prostatic gland if treatment was started immediately after diagnosis. We were interested to determine the duration of neo-adjuvant hormonal treatment, that within the 1st year resulted in maximal pre-radiotherapy downsizing of the prostatic gland.

As our investigated patients were randomized against a ‘non-treated’ control arm, we also had the possibility to study the volume change of the prostate during 1 year if no hormone manipulation was initiated, thus assessing the growth pattern of the cancerous prostate gland.

Section snippets

Patients and methods

In 1986 the EORTC-GU group initiated a phase III trial with T1 to T 3pN+M0 prostate cancer which in asymptomatic patients compared immediate androgen deprivation (IAD) with delayed androgen deprivation (DAD) and start of therapy in case of clinical progression (EORTC 30846). From the time of randomization patients within the IAD arm received 3.6 mg LHRH analogue (Zoladex®, Zeneca) every 4 weeks subcutaneously together with oral cyproterone acetate (Androcur®, Schering) 150 mg pd. during the 1st

Results

At randomization the two patients cohorts were similar in terms of age, pN status and tumour category (Table 1), though the mean volume of the DAD group was above that of the IAD group. This difference did not reach statistical significance.

In the IAD group the prostate gland size decreased in all patients with significant difference as compared with the DAD group (P=0.033, Fig. 2a,b). Pairwise comparison of mean values confirmed the volume reduction at months 1, 3 and 9 (P<0.05, Table 2).

Discussion

In the present study only 13 patients in the IAD group and 13 patients in the DAD group are investigated. These were those patients who were included in the EORTC trial 30846 by our institution. This trial required regular assessments of the prostate gland, preferably measured by ultrasonography. No other institution used CT/MR for such measurements. The results of our admittedly limited series are in agreement with analogue observations from other though not radiotherapy-related studies. We

References (20)

There are more references available in the full text version of this article.

Cited by (0)

View full text